批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2019/07/02 |
SUPPL-39(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/12/21 |
SUPPL-37(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/05/10 |
SUPPL-33(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2016/03/21 |
SUPPL-36(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/03/08 |
SUPPL-34(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2015/09/03 |
SUPPL-35(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2015/05/29 |
SUPPL-32(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2014/08/07 |
SUPPL-31(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2013/07/30 |
SUPPL-30(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2013/05/17 |
SUPPL-29(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2013/02/15 |
SUPPL-28(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2012/11/09 |
SUPPL-27(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2012/05/30 |
SUPPL-25(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
2010/06/23 |
SUPPL-23(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2005/11/30 |
SUPPL-11(补充) |
Approval |
Efficacy |
UNKNOWN
|
|
|
2005/09/02 |
SUPPL-14(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2005/06/13 |
SUPPL-6(补充) |
Approval |
Efficacy |
STANDARD
|
|
|
2004/05/07 |
SUPPL-9(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2002/06/20 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2001/06/22 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2001/05/14 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2001/04/02 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2000/12/15 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:BIVALIRUDIN 剂型/给药途径:INJECTABLE;INTRAVENOUS 规格:250MG/VIAL 治疗等效代码:AP
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020873 |
001 |
NDA |
ANGIOMAX |
BIVALIRUDIN |
INJECTABLE;INTRAVENOUS |
250MG/VIAL |
Prescription |
Yes |
Yes |
AP |
2000/12/15
|
SANDOZ |
090811 |
001 |
ANDA |
BIVALIRUDIN |
BIVALIRUDIN |
INJECTABLE;INTRAVENOUS |
250MG/VIAL |
Discontinued |
No |
No |
AP |
2015/07/14
|
HOSPIRA |
090816 |
001 |
ANDA |
BIVALIRUDIN |
BIVALIRUDIN |
INJECTABLE;INTRAVENOUS |
250MG/VIAL |
Discontinued |
No |
No |
AP |
2015/07/14
|
HOSPIRA |
090189 |
001 |
ANDA |
BIVALIRUDIN |
BIVALIRUDIN |
INJECTABLE;INTRAVENOUS |
250MG/VIAL |
Prescription |
No |
No |
AP |
2016/10/28
|
FRESENIUS KABI USA |
201577 |
001 |
ANDA |
BIVALIRUDIN |
BIVALIRUDIN |
INJECTABLE;INTRAVENOUS |
250MG/VIAL |
Prescription |
No |
No |
AP |
2017/05/26
|
DR REDDYS |
206551 |
001 |
ANDA |
BIVALIRUDIN |
BIVALIRUDIN |
INJECTABLE;INTRAVENOUS |
250MG/VIAL |
Prescription |
No |
No |
AP |
2017/11/22
|
ACCORD HLTHCARE |
202471 |
001 |
ANDA |
BIVALIRUDIN |
BIVALIRUDIN |
INJECTABLE;INTRAVENOUS |
250MG/VIAL |
Prescription |
No |
No |
AP |
2018/06/01
|
MYLAN INSTITUTIONAL |
091602 |
001 |
ANDA |
BIVALIRUDIN |
BIVALIRUDIN |
INJECTABLE;INTRAVENOUS |
250MG/VIAL |
Prescription |
No |
No |
AP |
2018/07/16
|
MEITHEAL |
205962 |
001 |
ANDA |
BIVALIRUDIN |
BIVALIRUDIN |
INJECTABLE;INTRAVENOUS |
250MG/VIAL |
Prescription |
No |
No |
AP |
2018/07/27
|
EUGIA PHARMA |
210031 |
001 |
ANDA |
BIVALIRUDIN |
BIVALIRUDIN |
INJECTABLE;INTRAVENOUS |
250MG/VIAL |
Prescription |
No |
No |
AP |
2019/10/23
|
SHUANGCHENG |
213078 |
001 |
ANDA |
BIVALIRUDIN |
BIVALIRUDIN |
INJECTABLE;INTRAVENOUS |
250MG/VIAL |
Prescription |
No |
No |
AP |
2021/05/28
|
SLATE RUN PHARMA |